Product Description
Azithromycin is an antimicrobial medication used to treat and manage bacterial infections, including community-acquired pneumonia and sexually transmitted diseases. It is in the macrolide class of antimicrobials.Azithromycin is a broad-spectrum macrolide antimicrobial and is among the most prescribed antimicrobial drugs in the United States. It is a derivative of erythromycin with greatly enhanced activity against gram-negative bacteria (including Enterobacteriaceae) and provides coverage of many gram-positive organisms (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557766/)
Mechanisms of Action: CYP3A4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, China, Czech Republic, Denmark, Finland, France, Germany, Ghana, Hungary, India, Indonesia, Israel, Italy, Korea, Lao, Mali, Nepal, Netherlands, New Zealand, Sierra Leone, South Africa, Spain, Taiwan, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia, Neonatal|COVID-19|Communicable Diseases|Diarrhea|Inflammation|Injuries/wounds Unspecified|Lung Transplant|Malaria|Measles|Mycobacterium Infections, Nontuberculous|Mycobacterium avium-intracellulare Infection|Nontuberculous Mycobacterial Lung Disease|Pneumonia|Severe Acute Respiratory Syndrome|Trachoma|Vision, Low
Phase 2: Brain Cancer|Glioblastoma
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2016-003339-39 |
2016-003339-39 | P3 |
Active, not recruiting |
Injuries/wounds Unspecified |
2019-02-28 |
2022-03-13 |
Treatments |
|
2020-002545-42 |
ARISE | P3 |
Completed |
Nontuberculous Mycobacterial Lung Disease |
2023-05-09 |
17% |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
NCT04677543 |
ARISE | P3 |
Completed |
Mycobacterium avium-intracellulare Infection|Communicable Diseases|Mycobacterium Infections, Nontuberculous |
2023-05-09 |
17% |
2024-06-28 |
Primary Endpoints |
ACTRN12619000640101p |
2006-7041-83/hah | P2 |
Not yet recruiting |
Glioblastoma|Brain Cancer |
2020-05-20 |
|||
NCT06082037 |
ROCKaspire | P3 |
Recruiting |
Lung Transplant |
2026-09-17 |
11% |
2024-05-11 |
Primary Endpoints|Treatments |
NCT04381936 |
RECOVERY | P3 |
Recruiting |
COVID-19|Severe Acute Respiratory Syndrome |
2026-06-30 |
2024-01-06 |
||
NCT04235816 |
ICARIA | P3 |
Active, not recruiting |
Measles|Pneumonia|Anemia, Neonatal|Diarrhea|Malaria|Trachoma |
2025-09-11 |
2025-07-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT05972772 |
RiCS | P3 |
Recruiting |
Communicable Diseases |
2025-08-31 |
2024-12-28 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT04424511 |
LAKANA | P3 |
Completed |
Vision, Low|Malaria|Inflammation |
2024-12-31 |
2025-05-22 |
Patient Enrollment|Primary Endpoints|Treatments |
|
CTR20171463 |
CTR20171463 | P1 |
Active, not recruiting |
Pneumonia |
None |
2025-04-29 |
||
NCT05966688 |
SPR720-102 | P1 |
Completed |
Healthy Volunteers |
2024-01-30 |
69% |
2024-03-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |